MDGL - Company ID 0001157601
MADRIGAL PHARMACEUTICALS, INC. trades as MDGL and has a market capitalization of $12.76 B, making it the #814 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $958.40M, up 432.1% from the prior year and net income of -$288.28M. This page tracks MADRIGAL PHARMACEUTICALS, INC. through 1,184 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 13 fiscal years MADRIGAL PHARMACEUTICALS, INC.'s revenue grew from $147.00K to $958.40M, a compound annual growth rate of 96.5%.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider sale notice | 144 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-18 |
| Insider sale notice | 144 | 2026-05-18 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-06 |
| Major company event | 8-K | 2026-05-06 |
| Major company event | 8-K | 2026-04-28 |
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | Madrigal Pharmaceuticals, Inc.
Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk | Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates | Madrigal Pharmaceuticals, Inc.
Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results.
The largest companies sharing MADRIGAL PHARMACEUTICALS, INC.'s SEC industry classification (pharmaceutical preparations).
MADRIGAL PHARMACEUTICALS, INC. (MDGL) has a market capitalization of $12.76 B as of 2026-07-09, ranking #814 among US-listed companies.
MADRIGAL PHARMACEUTICALS, INC. reported revenue of $958.40M for fiscal year 2025, an increase of 432.1% year over year.
In its latest fiscal year MADRIGAL PHARMACEUTICALS, INC. reported a net loss of $288.28M.